Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.80 -0.25% 1,489.40 1,491.80 1,492.80 1,507.00 1,469.80 1,496.00 8,590,242 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 15.9 74,724

Glaxosmithkline Share Discussion Threads

Showing 19051 to 19075 of 21100 messages
Chat Pages: Latest  772  771  770  769  768  767  766  765  764  763  762  761  Older
DateSubjectAuthorDiscuss
31/1/2019
13:01
How on earth ca she talk about deep science? No arts graduate is that clever. You need the background or else you lack credibility.
zicopele
31/1/2019
13:00
The Mylan copy was always coming - only surprise is that it took so long. Assuming that GSK cut their price the sales may hang around a bit longer due to the diskus device - some will want to stay with that rather than switching to something else. Ironically is also what Mylan say about the Epipen which they have jacked the price up on multiple times. Must say in the rare cases that I take medication I use generics. Same tablet in a different box in some case. I also tend to look to see where they are made and to see if I trust the lab (if I have been in there). Some are better than others.
dr biotech
31/1/2019
12:58
"She pays close attention to talent development but "can be ruthless with underperformers"." How long before she is ruthless with herself???
wbecki
31/1/2019
12:49
Emma has removed the old guard and surrounded herself with people who are experts in science. She is an extremely clever person and it has been said that she sets clear objectives and there’s lots of KPIs to measure delivery. She pays close attention to talent development but "can be ruthless with underperformers".
tradermichael
31/1/2019
12:36
@Zico, Nailed it.
wbecki
31/1/2019
12:18
Emma is a poster child for female empowerment. That is all very well but she does not have a background in science.
zicopele
31/1/2019
11:38
Even more pessimistic now. Monty is quoting an article from a young shyster in a smart suit. Please...please do not quote TMF. It is too much to bear.
zicopele
31/1/2019
11:31
Don't worry, Emma will talk about that with the results (next Wednesday).
tradermichael
31/1/2019
11:27
Not what some think, dividend will return to growth.https://www.fool.co.uk/investing/2018/12/13/why-the-gsk-share-price-is-a-ftse-100-dividend-growth-opportunity-id-buy-today/
montyhedge
31/1/2019
10:57
I was hoping for another six months to bed downTesaro acquisition and get Shingrix production levels up. Profits will fall this year. Dividend will be cut next year. Shame....should be do good.
zicopele
31/1/2019
10:55
But did you know: Unlike standard paracetamol tablets, GSK's Panadol Advance tablets and Panadol Extra Advance tablets contain Optizorb® Technology which allows the tablets to dissolve rapidly and be absorbed faster than standard paracetamol tablets
tradermichael
31/1/2019
10:55
Most of the large Pharmas distribute generic versions of products that are no longer protected, the major companies have Generic Licenses listed under a subsidiary name.
gbh2
31/1/2019
10:44
I buy Panadol that are a market leader. Who’s brand is that again.
deanowls
31/1/2019
10:40
btw to say that generic competition will not harm a franchise is nonsense; it will.
alphorn
31/1/2019
10:08
Amoxicillin is a well known antibiotic by GSK,for many years GSK has dominated the market in this field inspite of the presence of many generics,I am sure they will do the same fo Advair.
abdullla
31/1/2019
10:05
But it is good news such that the market can now move on and focus on GSK's other strengths. GSK has had nearly 3 years of borrowed time and that was after a good run with this world-beating drug and delivery system. All big drugs eventually get knocked back by generic competition. GSK has had time to deal with that - having set up extensive discounted contracts that Mylan will find it difficult to compete with and engineered adventurous deals with Novartis, Horlicks, Tesaro etc. Also, been able to launch Shingrix and develop the market ahead of Advair's slow demise.
tradermichael
31/1/2019
09:40
Glad I dont take these threads too seriously. Some of you guys would have me believe that generic Advair is actually a good news story. Mr Market thinks otherwise. GSK down on a good day.
zicopele
31/1/2019
09:33
IbuProfen ftw :) Paracetamol is so old school..
wbecki
31/1/2019
09:28
Sure Monty...Bet you never buy Paracetamol either. Keep up the good work.
zicopele
31/1/2019
09:00
I rather have the real thing than a knock off product. GSK plenty of projects in the pipeline. Not come out the blue that's why GSK shares are below 1500p.
montyhedge
31/1/2019
08:59
Mr market has marked mylan up 7% and GSK down 1%. Yes the market expected it but ....not quite yet. Always next week. Pity I did not wait for dividend cut before investing. Every dividend represents.destruction of future value.
zicopele
31/1/2019
08:47
Still, the generic Advair opportunity isn’t what it once was, Evercore ISI’s Umer Raffat wrote in his own note to clients. He predicted the knockoff could generate close to $250 million in 2019, while Fadia modeled an even lower $170 million in 2019 sales. “We know GSK has been aggressively discounting in this market,” he wrote, pointing out that when Mylan launches, many contracts could be locked in. “I've heard feedback from payors that GSK has worked very hard to lock in >80% of Part D plans using B4G (brand for generic) contracts for 2019 at least. Part D represents ~40% of market,” Raffat said. In an interview earlier this month, David Redfern, GSK’s chief strategy officer, called the room under the curve for generic Advair “very, very limited.”
tradermichael
31/1/2019
08:24
It was a question of when (not if). It took Mylan 5 years to get approval, so hardly a surprise - why do you think the 'market' has been so down on GSK all this time?
tradermichael
31/1/2019
08:20
Shingrix is excellent and will be $2bn a year in the future but will never replace advair. Great that they will compete but sales will fall off the cliff. Introdu tion of generic decimated sales.
zicopele
31/1/2019
08:16
They will never cut the dividend, shingles vac already a new blockbuster. Advair they will cut price and compete.
montyhedge
Chat Pages: Latest  772  771  770  769  768  767  766  765  764  763  762  761  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200404 02:44:24